The high expression of PD-L1 in pancreatic cancer is not effective with monoclonal antibody treatment, suggesting that PD-L1 has a tumor-promoting regulatory mechanism independent of PD-1. This evidence concerns the gene PDCD1 and pancreatic neoplasm.